Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit Suisse
September 21, 2017 6:26 AM EDTCredit Suisse analyst Alethia Young raised her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $123.00 (from $96.00) while maintaining an Outperform rating following positive APOLLO trial data.
Young thinks porphyria data in mid-2018 and patisiran's expansion into the cardiac subtype can continue... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company
September 20, 2017 3:20 PM EDTNeedham & Company analyst Alan Carr raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $85.00) while maintaining a Buy rating after the company announced positive top-line results from Phase 3 APOLLO trial in TTR Amyloidosis.
"Notably, primary mNIS+7 and key secondary Norfolk QOL-DN endpoint... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities
September 20, 2017 2:14 PM EDTJMP Securities analyst Michael King raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $101.00) while maintaining a Market Outperform rating after the company announced positive top-line results for the Phase III APOLLO trial.
"We believe patisirans success in APOLLO... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at Stifel
September 20, 2017 1:41 PM EDTStifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $83.00 (from $56.00) while maintaining a Hold rating.
... MoreAlnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'
September 20, 2017 12:36 PM EDTCowen raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $117.00 (from $93.00) while maintaining a Outperform rating after the company released positive top-line data from the pivotal Ph3 APOLLO trial of patisiran in FAP with strong statistical significance.
Analyst Ritu Baral... More
